These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 16609041

  • 1. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
    Rice JR, Gerberich JL, Nowotnik DP, Howell SB.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2248-54. PubMed ID: 16609041
    [Abstract] [Full Text] [Related]

  • 2. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov 01; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ, Kelland LR, Boxall FE, Valenti MR, Jones M, Goddard PM, Gwynne J, Harrap KR.
    Cancer Res; 1994 Aug 01; 54(15):4118-22. PubMed ID: 8033145
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
    Campone M, Rademaker-Lakhai JM, Bennouna J, Howell SB, Nowotnik DP, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2007 Sep 01; 60(4):523-33. PubMed ID: 17308894
    [Abstract] [Full Text] [Related]

  • 7. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
    Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, Joseph E, Hamburger DR, Working PK, Colbern G, Tonda ME, Potter DM, Eiseman JL.
    Cancer Chemother Pharmacol; 2004 Apr 01; 53(4):329-36. PubMed ID: 14673619
    [Abstract] [Full Text] [Related]

  • 8. ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic.
    Nowotnik DP, Cvitkovic E.
    Adv Drug Deliv Rev; 2009 Nov 12; 61(13):1214-9. PubMed ID: 19671439
    [Abstract] [Full Text] [Related]

  • 9. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
    Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP.
    Clin Cancer Res; 2004 May 15; 10(10):3386-95. PubMed ID: 15161693
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
    Kido Y, Khokhar AR, Yoshida M, Thai GW, Siddik ZH.
    Drug Metab Dispos; 1994 May 15; 22(2):312-7. PubMed ID: 8013287
    [Abstract] [Full Text] [Related]

  • 11. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
    Shord SS, Bernard SA, Lindley C, Blodgett A, Mehta V, Churchel MA, Poole M, Pescatore SL, Luo FR, Chaney SG.
    Anticancer Res; 2002 May 15; 22(4):2301-9. PubMed ID: 12174918
    [Abstract] [Full Text] [Related]

  • 12. Novel bis-platinum complexes endowed with an improved pharmacological profile.
    Gatti L, Perego P, Leone R, Apostoli P, Carenini N, Corna E, Allievi C, Bastrup U, De Munari S, Di Giovine S, Nicoli P, Grugni M, Natangelo M, Pardi G, Pezzoni G, Singer JW, Zunino F.
    Mol Pharm; 2010 Feb 01; 7(1):207-16. PubMed ID: 19919086
    [Abstract] [Full Text] [Related]

  • 13. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
    Boven E, van der Vijgh WJ, Nauta MM, Schlüper HM, Pinedo HM.
    Cancer Res; 1985 Jan 01; 45(1):86-90. PubMed ID: 4038381
    [Abstract] [Full Text] [Related]

  • 14. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts.
    Taetle R, Rosen F, Abramson I, Venditti J, Howell S.
    Cancer Treat Rep; 1987 Mar 01; 71(3):297-304. PubMed ID: 3815395
    [Abstract] [Full Text] [Related]

  • 15. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
    Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA, Tonda ME, Yu NY, Engbers C, Eiseman JL.
    Clin Cancer Res; 2007 Dec 01; 13(23):7217-23. PubMed ID: 18056203
    [Abstract] [Full Text] [Related]

  • 16. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB.
    Cancer Chemother Pharmacol; 2007 Feb 01; 59(3):301-12. PubMed ID: 16770583
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ, Moyer JD, Suffness M, Harrison SD, Cysyk R, Hamilton TC, Plowman J.
    Cancer Res; 1994 Feb 01; 54(3):724-9. PubMed ID: 8306334
    [Abstract] [Full Text] [Related]

  • 18. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 01; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 19. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
    Kim DK, Kim HT, Cho YB, Kim TS, Kim KH, Hong WS.
    Anticancer Res; 1996 Jun 01; 16(1):251-6. PubMed ID: 8615617
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
    Staffhorst RW, van der Born K, Erkelens CA, Hamelers IH, Peters GJ, Boven E, de Kroon AI.
    Anticancer Drugs; 2008 Aug 01; 19(7):721-7. PubMed ID: 18594214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.